Methods of preventing or treating cell malignancies by administering cd2 antagonists
CA 2497628 A1 · Owner: Medimmune, Inc. · Inventors: Zhang, Meili; Zhang, Zhuo; Waldmann, Thomas
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention encompasses the use of a CD2 antagonist preferably MEDI-, 507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment management, or amelioration of , cancer particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the use of a CD2 antagonist preferably , MEDI-507, an analog, derivative of an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts effective …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 5, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 5, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 5, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.